Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis
- PMID: 18768247
- DOI: 10.1016/j.ejogrb.2008.07.021
Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis
Abstract
Objectives: Gene expression analysis has identified several breast cancer subtypes, including luminal, epidermal growth factor receptor-2 positive (HER2+), and basal-like. To determine if our proposed molecular taxonomy correlates with biological and clinical behavior. This is based on four biological markers: estrogen and progesterone receptors (ER and PR, respectively), HER2 and the epidermal growth factor receptor-1 (HER1), all of them being determined by quantitative assays.
Study design: The biological parameters were examined by enzyme immunoassay, radioligand-binding assay or ELISA, in tumors from 787 patients with invasive breast cancer. Patients were prospectively evaluated over a median follow-up period of 50 months. Subtype definitions were as follows: luminal (ER+), HER2+ (HER2+, ER-, PgR-) and basal-like (HER2-, ER-, PgR-). In addition, we divided basal tumors into two groups based on their HER1 status.
Results: A 55.8% of tumors were of luminal type, 11.9% basal-like HER1+, 10.7 basal-like HER1-, and the remainder 21.6% HER2+. Both HER2+ and basal-like subtypes were more frequent in younger and premenopausal women, showing a higher percentage of cases of poorly differentiated tumors and higher S-phase fraction, when compared with those of luminal subtype. Multivariate analysis demonstrated that the subtype of tumor was related to both relapse and overall survival, being those of luminal subtype associated with the best prognosis.
Conclusions: Through the classification of breast tumors in four groups, according to their ER, PgR, HER2 and HER1 status, it is possible to obtain a major division of breast tumors associated with significant differences in biological features and clinical behavior.
Similar articles
-
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res. 2007 Apr 15;13(8):2329-34. doi: 10.1158/1078-0432.CCR-06-1109. Clin Cancer Res. 2007. PMID: 17438091
-
[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19950556 Chinese.
-
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.Hum Pathol. 2006 Sep;37(9):1217-26. doi: 10.1016/j.humpath.2006.04.015. Epub 2006 Jul 18. Hum Pathol. 2006. PMID: 16938528
-
Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.J Cell Physiol. 2006 Dec;209(3):645-52. doi: 10.1002/jcp.20785. J Cell Physiol. 2006. PMID: 17001676 Review.
-
Gene-expression analysis and the basal-like breast cancer subtype.Future Oncol. 2007 Feb;3(1):55-63. doi: 10.2217/14796694.3.1.55. Future Oncol. 2007. PMID: 17280502 Review.
Cited by
-
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.Breast Cancer Res Treat. 2011 Apr;126(3):671-8. doi: 10.1007/s10549-010-1148-9. Epub 2010 Sep 3. Breast Cancer Res Treat. 2011. PMID: 20814817 Free PMC article.
-
Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients.Open Access Maced J Med Sci. 2018 Jun 6;6(6):961-967. doi: 10.3889/oamjms.2018.231. eCollection 2018 Jun 20. Open Access Maced J Med Sci. 2018. PMID: 29983785 Free PMC article.
-
Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.Curr Oncol. 2013 Dec;20(6):e539-45. doi: 10.3747/co.20.1523. Curr Oncol. 2013. PMID: 24311954 Free PMC article.
-
Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.J Med Chem. 2009 Aug 27;52(16):5124-43. doi: 10.1021/jm9005803. J Med Chem. 2009. PMID: 19653647 Free PMC article.
-
Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis.BMC Cancer. 2010 May 11;10:191. doi: 10.1186/1471-2407-10-191. BMC Cancer. 2010. PMID: 20459777 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous